Portfolio

Investing in A Better World!

Industry: BioPharma

  • MindBio Therapeutics Corp (CSE:MBIO).

    A significant milestone for MindBio is the successful completion of Phase 1 and Phase 2A clinical trials over the past 4 years reporting positive top line and sustainability data. MindBio’s lead candidate drug MB22001 has shown in clinical trials to significantly improve mood and sleep and reduce depressive symptoms by 72%.

    MindBio is the only organization in the world to have obtained regulatory approvals for at-home use of a psychedelic medicine in clinical trials. At-home use is crucial for testing and modeling the safety and efficacy of psychedelics within the community, as the company strives to have these life-saving medicines approved.

    MindBio has two fully funded Phase 2B clinical trials underway due for completion in late 2025. The first trial focuses on Major Depressive Disorder, where patients will receive MindBio’s MB22001 treatment regimen in a naturalistic at-home setting over 8 weeks.

    The second Phase 2B clinical trial currently underway and dosing due for completion late 2025 is testing MB22001 in late stage cancer patients experiencing emotional distress, anxiety and depression.

    All Blackhawk Growth Shareholders at the time of the spin out of MindBio Therapeutics Corp received a 1:1 shareholding in Mindbio.

  • The company successfully listed on the Canadian Securities Exchange on May 2023 under the ticker MBIO.

    All shareholders in Blackhawk Growth Corp at the time of the spin out of MindBio Theapeutics Corp, received a 1:1 shareholding in MindBio.

Industry: New Deals Coming Soon

  • The company is reviewing a number of new opportunities to invest in, related to technology, health, AI and machine learning.

  • Contact us and register your interest to get early access to potential investment opportunities and private placements.

MindBio Therapeutics – A Case Study in Success

Background

MindBio Therapeutics Corp. (CSE: MBIO) is a biotechnology company specializing in psychedelic medicine research and development. The company focuses on innovative treatment solutions for mental health conditions, including depression and anxiety using microdoses of a psychedelic medicine (MB22001).

Blackhawk’s Role in MindBio's Success

•Acquisition & Incubation: Blackhawk Growth acquired MindBio during its early stages and provided funding and strategic support.

•Brand Development: Assisted in establishing a strong market presence and thought leadership.

•Successful Spin-Out & Public Listing: MindBio was successfully spun out and listed on the Canadian Securities Exchange under the ticker MBIO.

Impact

MindBio Therapeutics has emerged as a leader in psychedelic medicine research, with ongoing clinical trials and collaborations with leading healthcare institutions. It boasts leading edge technology in speech analysis and drug detection.

Listed on Canadian Securities Exchange (CSE:MBIO).  Multiple successful clinical trials.  Two Phase 2B randomized controlled clinical trials currently underway with top line readouts due end 2025.